The board of Vimta Labs at its meeting held on 28 April 2025 has approved the company's foray into Biologics Contract Research and Development with an investment of Rs 50 crore. The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides.
Powered by Capital Market - Live News